Nanobiotix S.A [NBTX] vs Vertex [VRTX] Detailed Stock Comparison
Nanobiotix S.A
NASDAQ
Loading...
Vertex
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Nanobiotix S.A wins in 12 metrics, Vertex wins in 4 metrics, with 0 ties. Nanobiotix S.A appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Nanobiotix S.A | Vertex | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -4.83 | 32.82 | Nanobiotix S.A |
| Price-to-Book Ratio | N/A | 7.05 | N/A |
| Debt-to-Equity Ratio | -0.90 | 8.89 | Nanobiotix S.A |
| PEG Ratio | -2.75 | 25.16 | Nanobiotix S.A |
| EV/EBITDA | -4.78 | 24.22 | Nanobiotix S.A |
| Profit Margin (TTM) | 0.00% | 31.86% | Vertex |
| Operating Margin (TTM) | 271.42% | 38.93% | Nanobiotix S.A |
| EBITDA Margin (TTM) | 271.42% | 38.93% | Nanobiotix S.A |
| Return on Equity | 103.70% | 22.77% | Nanobiotix S.A |
| Return on Assets (TTM) | -52.89% | 13.09% | Vertex |
| Free Cash Flow (TTM) | $-20.40M | $-978.00M | Nanobiotix S.A |
| 1-Year Return | 41.39% | -17.68% | Nanobiotix S.A |
| Price-to-Sales Ratio (TTM) | -45.76 | 10.62 | Nanobiotix S.A |
| Enterprise Value | $374.97M | $116.19B | Vertex |
| EV/Revenue Ratio | -45.00 | 10.18 | Nanobiotix S.A |
| Gross Profit Margin (TTM) | N/A | 86.90% | N/A |
| Revenue per Share (TTM) | $0 | $44 | Vertex |
| Earnings per Share (Diluted) | $-1.67 | $-3.83 | Nanobiotix S.A |
| Beta (Stock Volatility) | 1.50 | N/A | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Nanobiotix S.A vs Vertex Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Nanobiotix S.A | 2.64% | 4.05% | 50.10% | 117.88% | 81.57% | 147.93% |
| Vertex | -2.49% | -17.78% | -18.24% | -13.61% | -19.96% | -7.43% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Nanobiotix S.A | 41.39% | 69.12% | -59.36% | -59.36% | -59.36% | -59.36% |
| Vertex | -17.68% | 30.94% | 44.28% | 181.74% | 965.63% | 2,177.91% |
Performance & Financial Health Analysis: Nanobiotix S.A vs Vertex
| Metric | NBTX | VRTX |
|---|---|---|
| Market Information | ||
| Market Cap | $329.01M | $121.28B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 11,320 | 1,390,330 |
| 90 Day Avg. Volume | 5,990 | 1,229,373 |
| Last Close | $7.38 | $366.29 |
| 52 Week Range | $2.76 - $7.74 | $364.66 - $519.88 |
| % from 52W High | -4.65% | -29.54% |
| All-Time High | $21.55 (Dec 14, 2020) | $519.88 (Nov 04, 2024) |
| % from All-Time High | -65.75% | -29.54% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.12% |
| Quarterly Earnings Growth | N/A | 0.03% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.32% |
| Operating Margin (TTM) | 2.71% | 0.39% |
| Return on Equity (TTM) | 1.04% | 0.23% |
| Debt to Equity (MRQ) | -0.90 | 8.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-1.39 | $67.01 |
| Cash per Share (MRQ) | $1.05 | $24.90 |
| Operating Cash Flow (TTM) | $-22,660,391 | $-562,900,000 |
| Levered Free Cash Flow (TTM) | $-38,427,971 | $-438,500,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Nanobiotix S.A vs Vertex
| Metric | NBTX | VRTX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -4.83 | 32.82 |
| Forward P/E | -2.75 | 25.16 |
| PEG Ratio | -2.75 | 25.16 |
| Price to Sales (TTM) | -45.76 | 10.62 |
| Price to Book (MRQ) | N/A | 7.05 |
| Market Capitalization | ||
| Market Capitalization | $329.01M | $121.28B |
| Enterprise Value | $374.97M | $116.19B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | -45.00 | 10.18 |
| Enterprise to EBITDA | -4.78 | 24.22 |
| Risk & Other Metrics | ||
| Beta | 1.50 | N/A |
| Book Value per Share (MRQ) | $-1.39 | $67.01 |
Financial Statements Comparison: Nanobiotix S.A vs Vertex
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NBTX | VRTX |
|---|---|---|
| Revenue/Sales | N/A | $2.96B |
| Cost of Goods Sold | N/A | $407.50M |
| Gross Profit | N/A | $2.56B |
| Research & Development | N/A | $978.40M |
| Operating Income (EBIT) | N/A | $1.15B |
| EBITDA | N/A | $1.34B |
| Pre-Tax Income | N/A | $1.28B |
| Income Tax | N/A | $250.10M |
| Net Income (Profit) | N/A | $1.03B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NBTX | VRTX |
|---|---|---|
| Cash & Equivalents | $49.74M | $4.67B |
| Total Current Assets | $61.47M | $10.01B |
| Total Current Liabilities | $58.94M | $3.78B |
| Long-Term Debt | $45.98M | $1.65B |
| Total Shareholders Equity | $-65.70M | $16.50B |
| Retained Earnings | $-68.13M | $10.25B |
| Property, Plant & Equipment | $2.49M | $2.63B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NBTX | VRTX |
|---|---|---|
| Operating Cash Flow | N/A | $404.90M |
| Capital Expenditures | N/A | $-40.70M |
| Free Cash Flow | N/A | $778.20M |
| Debt Repayment | N/A | $-1.30M |
| Common Stock Repurchase | N/A | $-696.60M |
Short Interest & Institutional Ownership Analysis
| Metric | NBTX | VRTX |
|---|---|---|
| Shares Short | 6,060 | 4.19M |
| Short Ratio | 1.56 | 3.34 |
| Short % of Float | 0.00% | 0.02% |
| Average Daily Volume (10 Day) | 11,320 | 1,390,330 |
| Average Daily Volume (90 Day) | 5,990 | 1,229,373 |
| Shares Outstanding | 47.40M | 256.94M |
| Float Shares | 24.67M | 255.58M |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.12% | 0.98% |
Dividend Analysis & Yield Comparison: Nanobiotix S.A vs Vertex
| Metric | NBTX | VRTX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |